Astaxanthin for Stage IV Cancer

Also known as: AstaREAL, Haematococcus pluvialis extract

Astaxanthin modulates tumor immunity and inhibits cancer cell proliferation through multiple non-toxic mechanisms.

Mechanism of Action

Astaxanthin enhances NK cell cytotoxicity, promotes T cell proliferation, inhibits NF-κB in tumor cells, suppresses STAT3 signaling, and reduces cancer stem cell self-renewal. Its anti-angiogenic effects complement immune enhancement.

General mechanism: Carotenoid antioxidant spanning lipid bilayers. Nrf2 activator, NF-κB/STAT3 inhibitor, mitochondrial membrane protector.

Current Evidence

Preclinical evidence across multiple cancer models. Epidemiological data suggests carotenoid intake reduces cancer risk. Human anti-cancer trials are early.

Clinical Status: Preclinical and epidemiological support. Safety data from other applications.

Safety Profile

Very safe. Naturally occurring. FDA GRAS status. No significant side effects. May cause orange skin tint at very high doses.

Key Research Questions

View glossary entry →

← Back to Stage IV Cancer Research